VRTX
Vertex Pharmaceuticals Incorporated
Income statement
| USDLine, in USD | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 13.0B | 12.0B | 11.0B | 9.9B | 8.9B | 7.6B | 6.2B | 4.2B | 3.0B | 2.5B | 1.7B | 1.0B | 580M | 1.2B | 1.5B | 1.4B | 143M | 102M | 176M |
Cost of revenue | 1.87B | 1.65B | 1.53B | 1.26B | 1.08B | 0.90B | 0.74B | 0.55B | 0.41B | 0.28B | 0.21B | 0.12B | 40M | 89M | 0.24B | 64M | 0 | — | — |
| Gross profit | 11.1B | 10.4B | 9.5B | 8.6B | 7.9B | 6.7B | 5.5B | 3.6B | 2.6B | 2.2B | 1.5B | 915M | 541M | 1.1B | 1.3B | 1.3B | 143M | — | — |
| 4.25B | 3.91B | 3.63B | 3.16B | 2.54B | 3.05B | 1.83B | 1.75B | 1.42B | 1.32B | 1.05B | 1.00B | 0.86B | 0.88B | 0.77B | 0.71B | 0.64B | 0.55B | 0.52B | |
| 2.41B | 1.75B | 1.46B | 1.14B | 0.94B | 0.84B | 0.77B | 0.66B | 0.56B | 0.50B | 0.43B | 0.38B | 0.31B | 0.36B | 0.43B | 0.40B | 0.19B | 0.13B | 0.10B | |
Other operating expenses | 0.12B | 0.51B | 4.63B | 0.48B | 58M | — | 13M | 4.5M | 29M | 0.27B | — | 9.6M | 72M | 0.49B | 45M | 0.12B | 14M | — | — |
| Operating income | 4.30B | 4.17B | −0.23B | 3.83B | 4.31B | 2.78B | 2.86B | 1.20B | 0.64B | 0.12B | 9.9M | −0.47B | −0.69B | −0.61B | 47M | 0.11B | −0.70B | −0.61B | −0.46B |
Non-operating income | 455M | 470M | 481M | 548M | −75M | −52M | 261M | 197M | −35M | −139M | −77M | −91M | −42M | −16M | −15M | −53M | −59M | −28M | 2.9M |
| Pretax income | 4.76B | 4.64B | 0.25B | 4.38B | 4.23B | 2.73B | 3.12B | 1.39B | 0.60B | −16M | −67M | −0.56B | −0.73B | −0.63B | 32M | 60M | −0.75B | −0.64B | −0.46B |
Taxes | 0.78B | 0.69B | 0.78B | 0.76B | 0.91B | 0.39B | 0.41B | 0.22B | −1.50B | −0.28B | 45M | −1.5M | 3.7M | −0.18B | 0.14B | 31M | 0 | 0 | 0 |
| Net income | 3.98B | 3.95B | −0.54B | 3.62B | 3.32B | 2.34B | 2.71B | 1.18B | 2.10B | 0.26B | −0.11B | −0.56B | −0.74B | −0.45B | −0.11B | 30M | −0.75B | −0.64B | −0.46B |
| Diluted EPS | 15.54 | 15.32 | −2.08 | 13.89 | 12.82 | 9.01 | 10.29 | 4.51 | 8.09 | 1.04 | −0.46 | −2.31 | −3.14 | −1.98 | −0.50 | 0.14 | −3.77 | −3.71 | −3.27 |
| Diluted shares | — | 258.0M | 257.9M | 260.5M | 259.1M | 259.9M | 263.4M | 260.7M | 259.2M | 253.2M | 244.7M | 241.3M | 235.3M | 224.9M | 215.3M | 208.8M | 200.4M | 173.3M | 140.6M |
| Revenue growth | — | +8.9% | +11.7% | +10.5% | +17.9% | +22.1% | +49.1% | +36.6% | +22.5% | +46.2% | +64.9% | +77.9% | −52.1% | −20.6% | +8.3% | +883.9% | +40.7% | −41.9% | — |
| Gross margin | 85.5% | 86.2% | 86.1% | 87.2% | 87.9% | 88.1% | 88.1% | 86.8% | 86.6% | 88.9% | 87.6% | 88.7% | 93.2% | 92.7% | 84.5% | 95.5% | 100.0% | — | — |
| Operating margin | 33.2% | 34.8% | −2.1% | 38.8% | 48.2% | 36.7% | 46.0% | 28.8% | 20.8% | 5.0% | 0.6% | −45.2% | −119.3% | −50.3% | 3.1% | 8.1% | −485.5% | −602.6% | −263.6% |
| Net margin | 30.7% | 32.9% | −4.9% | 36.7% | 37.2% | 30.9% | 43.7% | 28.3% | 68.8% | 10.6% | −6.6% | −53.9% | −127.2% | −36.7% | −7.0% | 2.1% | −526.3% | −630.3% | −262.0% |